In this single-arm, phase 2, nonrandomized clinical trial of 67 patients with ERBB2-positive early breast cancer, the overall pathologic complete response rate of 6 cycles of neoadjuvant PATH regimen was 61%. This evidence concerns the gene ERBB2 and breast cancer.